Clinical Trials Browser

Phase 2/3 × OTHER × nimotuzumab × Clear all

NCT06409429 2024-05-10

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02272699 2021-03-18

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Phase 2/3 Withdrawn

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT01402180 2011-07-26

Nimotuzumab

Phase 2/3 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma